Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-Van Den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen^*, Anthonie J. van der Wekken

^*Corresponding author voor dit werk

Onderzoeksoutput: Article › Academic › peer review

10 Citaten (Scopus)

83 Downloads (Pure)

10 Citaties
1 Erratum

1 resultaten

2024

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)
Gijtenbeek, R. G. P., van der Noort, V., Aerts, J. G. J. V., Staal-Van Den Brekel, J. A., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hiltermann, T. J. N., Timens, W., Schuuring, E., Janssen, J. D. J., Goosens, M., van den Berg, P. M., de Langen, A. J., Stigt, J. A., van den Borne, B. E. E. M., Groen, H. J. M., van Geffen, W. H. & van der Wekken, A. J., 1-jan.-2024, In: ERJ Open Research. 10, 1, 50239-2022.
Onderzoeksoutput

Open Access

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Onderzoekersoutput

Zoekresultaten

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)